GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 30 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1731 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
GlaxoSmithKline has agreed to sell a portfolio of international OTC brands, excluding the troubled anti-obesity drug alli® (orlistat, 60 mg), to South Africa’s Aspen Pharmacare for £164 M (US$263 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS